Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy

Leukemia & Lymphoma
Carlo ViscoAndreas H Sarris

Abstract

Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if > or = 10 pg/ml. We identified 69 patients with median age of 34 years (range 16 - 74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and beta2-microglobulin were independently associated with inferior...Continue Reading

References

Jul 1, 1988·Clinical Radiology·E VergerA Horwich
Jun 1, 1988·American Journal of Clinical Oncology·E J HallN Oleinick
Jun 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R FarahR Weichselbaum
Oct 1, 1986·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·A HorwichM J Peckham
Feb 1, 1984·International Journal of Radiation Oncology, Biology, Physics·M TubianaE van der Schueren
Jul 4, 1995·International Journal of Cancer. Journal International Du Cancer·K OhshimaM Kikuchi
Dec 1, 1993·International Immunology·K TagaG Tosato
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A RuedaJ Miramón
Jun 17, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A H SarrisF Cabanillas
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K H BackstrandP M Mauch

❮ Previous
Next ❯

Citations

Feb 18, 2016·British Journal of Cancer·Hua WangYue Lu
Apr 6, 2007·British Journal of Haematology·Je-Jung LeeYeon Hee Park
Mar 29, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·René-Olivier CasasnovasUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte
Jun 23, 2015·Immunology Letters·Maria Teresa P de AquinoAnil Shanker
Dec 29, 2007·The Journal of Pathology·C M Filippi, M G von Herrath
Aug 18, 2020·Cancer Management and Research·Di WangJinming Yu
Aug 18, 2018·Journal of Hematology & Oncology·Yang LiuJinming Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.